<unk>  is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface. In the absence of PCSK9, there are more LDL receptors on the surface of liver cells to remove LDL-C from the blood.
Evolocumab
Olaratumab
Emapalumab
Ustekinumab
Alirocumab
Tralokinumab
Anifrolumab
Dupilumab